Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo

Zhang, Yuxing; Wang, Chao; Wang, Haiwei; Wang, Kankan; Du, Yanzhi; Zhang, Ji

doi:10.1016/j.canlet.2011.01.022

Cited by 53 publications

(39 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with previous studies [30][31][32], the A2780 cells viability was markedly reduced by 10μM DDP while that of the OVCAR3 cells was 100μM DDP (Figure 2A, 2B). Considering to ABCG2 and MDR1 belong to the ABC transporter family, the well-characterized drug efflux transporters causing drug resistance in cancer cells [33], we next investigated whether rhIL-17A might change ABCG2 and MDR1 levels in OVCA cells.…”

Section: Rhil-17a Promotes the Ddp-resistance Of Ovca Cells Via Il-17rasupporting

confidence: 92%

IL-17A exacerbates cisplatin-based resistance of OVCA via upregulating the expression of ABCG2 and MDR1 through Gli1-mediated Hh signaling

Niu¹,

Liu²,

Wang³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

The major obstacle of the tumor chemotherapy, including ovarian cancer (OVCA), is drug resistance. However, the relevance of IL-17A with drug-resistance of OVCA has been poorly elaborated. In this study, we used 2 human OVCA cell lines to investigate the effects of IL-17A on cisplatin (CDDP or DDP)-based resistance in OVCA cells and the underlying mechanisms. Meanwhile, IL-17A-deficient mice and ID8 were used to verify the IL-17A's effects on OVCA chemo-resistance in vivo. Moreover, the relationship between IL-17A level and relevant indices were primarily assessed in ovarian specimens from 55 patients with OVCA. We found that rhIL-17A exacerbated DDP-based resistance of OVCA cells via up-regulating the expression of ABCG2 and MDR1 through Gli1-mediated Hh signal pathway. Animal experiment demonstrated that IL-17A significantly recede DDP-based treatment for ID8 tumor. Similar results were observed in preliminary clinical investigation. Our findings suggest that inhibiting IL-17A/IL-17RA-Gli1 signal may improve the resistance of OVCA to DDP.

show abstract

Section: Rhil-17a Promotes the Ddp-resistance Of Ovca Cells Via Il-17rasupporting

confidence: 92%

IL-17A exacerbates cisplatin-based resistance of OVCA via upregulating the expression of ABCG2 and MDR1 through Gli1-mediated Hh signaling

Niu¹,

Liu²,

Wang³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Mice treated with combination therapy showed a slightly improved tumor delay compared to mice treated with immunotherapy alone, in line with our expectation that cisplatin administered after the induction phase has no negative but rather a positive effect on tumor inhibition. Cisplatin is known for the treatment of several cancers, including non-small cell lung cancer, testicular cancer, ovarian cancer and cervical cancer [42][43][44][45][46][47], and is also known for its immunomodulatory properties. It has been reported that cisplatin induces MHC class I expression, increased susceptibility of tumor cells to CTL killing, a decrease in myeloid suppressor cells in the spleen and peripheral blood of tumor-bearing mice and activation of NK cells [48,49].…”

Section: ] Cxcl10 (Ip-10) Ccl5 (Rantes)mentioning

confidence: 99%

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

Fotin‐Mleczek

Zanzinger

Heidenreich

et al. 2012

The Journal of Gene Medicine

View full text Add to dashboard Cite

Direct vaccination with mRNA encoding tumor antigens is a novel and promising approach in cancer immunotherapy. CureVac's mRNA vaccines contain free and protamine-complexed mRNA. Such two-component mRNA vaccines support both antigen expression and immune stimulation. These self-adjuvanting RNA vaccines, administered intradermally without any additional adjuvant, induce a comprehensive balanced immune response, comprising antigen specific CD4+ T cells, CD8+ T cells and B cells. The balanced immune response results in a strong anti-tumor effect and complete protection against antigen positive tumor cells. This tumor inhibition elicited by mRNA vaccines is a result of the concerted action of different players. After just two intradermal vaccinations, we observe multiple changes at the tumor site, including the up-regulation of many genes connected to T and natural killer cell activation, as well as genes responsible for improved infiltration of immune cells into the tumor via chemotaxis. The two-component mRNA vaccines induce a very fast and boostable immune response. Therefore, the vaccination schedules can be adjusted to suit the clinical situation. Moreover, by combining the mRNA vaccines with therapies in clinical use (chemotherapy or anti-CTLA-4 antibody therapy), an even more effective anti-tumor response can be elicited. The first clinical data obtained from two separate Phase I/IIa trials conducted in PCA (prostate cancer) and NSCLC (non-small cell lung carcinoma) patients have shown that the twocomponent mRNA vaccines are safe, well tolerated and highly immunogenic in humans.

show abstract

“…However, the usage of CDDP is limited because of toxic effects on the tissue and organs such as ovary, kidney, liver etc. at high dose (Dillioglugil et al 2005;Naziroglu et al 2004;Zhang et al 2011;Ueki et al 2013). Numerous mechanisms contribute to the harmful effect.…”

Section: Introductionmentioning

confidence: 99%

“…Cells develop various protective mechanisms to protect from oxidative stress. Superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) activities are increased in cellular membranes due to CDDP induced nephrotoxicity (Noori and Mahboob 2010;Naqshbandi et al 2012;Ueki et al 2013), hepatoxicity (Mansour et al 2006;Kart et al 2010;Longo et al 2011), ovarian toxicity (Gupta et al 2006;Zhang et al 2011). These antioxidant enzymes play an important role to avoid the oxidative injury (Gupta et al 2006).…”

Section: Introductionmentioning

confidence: 99%

Protective effect of bilberry (Vaccinium myrtillus L.) on cisplatin induced ovarian damage in rat

Pandır

Kara

2013

Cytotechnology

View full text Add to dashboard Cite

Cisplatin is one of the most effective chemotherapeutic agents but injury may occur at higher doses. The aim of this study was to investigate the effect of bilberry on cisplatin induced toxic effects in rat ovary. Twenty-one female Wistar-Albino rats were utilized to form three groups: In group 1 (control group), each rat received intraperitoneal injection of 1 mL of 0.9 % NaCl saline solution during 10

show abstract

Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo

Cited by 53 publications

References 35 publications

IL-17A exacerbates cisplatin-based resistance of OVCA via upregulating the expression of ABCG2 and MDR1 through Gli1-mediated Hh signaling

IL-17A exacerbates cisplatin-based resistance of OVCA via upregulating the expression of ABCG2 and MDR1 through Gli1-mediated Hh signaling

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

Protective effect of bilberry (Vaccinium myrtillus L.) on cisplatin induced ovarian damage in rat

Contact Info

Product

Resources

About